A Pilot Study of NKTR-214 and Nivolumab in Selected Patients With Locally Advanced/Metastatic Sarcoma (CA209-9EM)
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary)
- Indications Alveolar soft part sarcoma; Chondrosarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Sarcoma
- Focus Therapeutic Use
- 04 Jan 2019 Planned End Date changed from 1 Sep 2019 to 1 Apr 2020.
- 04 Jan 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Apr 2020.
- 06 Jun 2018 Planned number of patients changed from 60 to 100.